Valeant Pays $12M To Settle Wellbutrin Antitrust Claims
Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of...To view the full article, register now.
Already a subscriber? Click here to view full article